natgillin/translations-raw huggingface dataset:
Zoledronic acid Teva treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Liječenje bolesnika Zoledronatnom kiselinom Teva s hiperkalcemijom izazvanom tumorom koji imaju i teško oštećenje funkcije bubrega dolazi u obzir tek nakon procjene rizika i koristi od liječenja.
Zoledronic Acid Teva treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje Zoledronatnom kiselinom Teva smije se nastaviti istom dozom koja se davala prije prekida liječenja.
Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje zoledronatnom kiselinom smije se nastaviti istom dozom koja se davala prije prekida liječenja.
Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje zoledronatnom kiselinom smije se nastaviti istom dozom koja se primjenjivala prije prekida liječenja.
Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation.
Moguće nuspojave zoledronatne kiseline na plodnost ispitani su na roditeljskoj i F1 generaciji štakora.
Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation.
Moguće nuspojave zoledronatne kiseline na plodnost, ispitani su na roditeljskoj i F1 generaciji štakora.
Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential.
Zoledronatna kiselina nije pokazala mutagenost na provedenim testovima mutagenosti, a ispitivanje karcinogenosti nije pružilo nikakav dokaz karcinogenog potencijala.
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6–3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledronatna kiselina je ispitivana u bolesnika oba spola koji su bili stariji od 30 godina i u kojih je radiološki potvrđena primarno blaga do umjerena Pagetova bolest kosti (u vrijeme ulaska u kliničko ispitivanje medijan razine alkalne fosfataze u serumu bio je 2,6 - 3,0 puta veći od gornje granice normalnog referentnog raspona specifičnog za tu dob).
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget’s disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledronatna kiselina ispitivana je u bolesnika oba spola koji su bili stariji od 30 godina i u kojih je radiološki potvrđena primarno blaga do umjerena Pagetova bolest kosti (u vrijeme ulaska u kliničko ispitivanje medijan razine alkalne fosfataze u serumu (SAP) bio je 2,6-3,0 puta veći od gornje granice normalnog referentnog raspona specifičnog za tu dob).
Zolpidem
hidrokodon
Zolpidem 5 200, 4 doses ↑ 28% ↑ 22% Zolpidem and ritonavir may be co-administered with careful monitoring for excessive sedative effects.
Zolpidem 5 200, 4 doze ↑ 28% ↑ 22% Zolpidem i ritonavir mogu se davati istodobno, uz pažljivo praćenje radi sprečavanja eventualnih pretjeranih sedacijskih učinaka.
ZOLVIX 25 mg/ml oral solution for sheep
ZOLVIX 25 mg/ml peroralna otopina za ovce
ZOLVIX 25 mg/ml oral solution for sheep Monepantel
ZOLVIX 25 mg/ml peroralna otopina za ovce Monepantel
ZOLVIX oral solution is a broad spectrum anthelmintic for the treatment and control of gastro- intestinal nematode infections and associated diseases in sheep including lambs, hoggets, breeding rams and ewes.
Peroralna otopina ZOLVIX je antihelmintik širokog spektra za liječenje i kontrolu probavnih infestacija nematodama i pridruženih bolesti ovaca uključujući janjce, omaše, rasplodne ovnove i ovce.
ZOLVIX was shown to be effective against strains of gastro-intestinal parasites, listed in section 4.2, resistant to (pro)benzimidazoles, levamisole, morantel, macrocyclic lactones and H. contortus strains resistant to salicylanilides.
Pokazalo se da je ZOLVIX učinkovit protiv želučano-crijevnih parazita, navedenih u dijelu 4.2, rezistentnih na (pro) benzimidazole, levamizol, morantel, makrocikličke laktone i sojeve H. contortus rezistentne na salicilanilide.
Zomarist 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Zomarist 50 mg/850 mg filmom obložene tablete su žute, ovalne tablete s oznakom „NVR” na jednoj strain i „SHE” na drugoj strani.
Zomarist is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multi- packs containing 120 (2x60), 180 (3x60) or 360 (6x60) film-coated tablets.
Zomarist je dostupan u pakiranjima od 10, 30, 60, 120, 180 ili 360 filmom obloženih tableta i u višestrukim pakiranjima od 120 (2x60), 180 (3x60) ili 360 (6x60) filmom obloženih tableta.
Zomarist is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
Zomarist je indiciran u kombinaciji sa sulfonilurejom (tj. trojna kombinirana terapija) kao dodatak dijeti i tjelovježbi u odraslih bolesnika u kojih je kontrola nedostatna s metforminom i sulfonilurejom.
Zomarist is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Zomarist je indiciran u liječenju odraslih bolesnika u kojih se ne može postići zadovoljavajuća kontrola glikemije primjenom oralnog metformina u maksimalno podnošljivoj dozi ili u bolesnika koji se već liječe kombinacijom odvojenih tableta vildagliptina i metformina.
Zomarist is indicated in the treatment of type 2 diabetes mellitus:
Zomarist je indiciran u liječenju šećerne bolesti tipa 2:
Zomarist is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Zomarist je indiciran u trojnoj kombiniranoj terapiji sa inzulinom kao dodatak dijeti i tjelovježbi za poboljšanje kontrole glikemije u odraslih bolesnika u kojih stabilna doza inzulina i metformina ne omogućuju odgovarajuću kontrolu glikemije.
Zomarist is used to treat adult patients with type 2 diabetes.
Zomarist se primjenjuje za liječenje bolesnika sa šećernom bolešću tipa 2.
Zomarist should not be used in patients with creatinine clearance < 60 ml/min (see sections 4.3, 4.4 and 5.2).
Zomarist se ne smije primjenjivati u bolesnika s klirensom kreatinina <60 ml/min (vidjeti dijelove 4.3, 4.4 i 5.2).
Zometa 4 mg powder and solvent for solution for infusion Zoledronic acid
Zometa 4 mg prašak i otapalo za otopinu za infuziju zoledronatna kiselina
Zometa 4 mg powder for solution for infusion Zoledronic acid
Zometa 4 mg prašak za otopinu za infuziju zoledronatna kiselina
Zometa 4 mg/100 ml solution for infusion Zoledronic acid
Zometa 4 mg/100 ml otopina za infuziju zoledronatna kiselina
Zometa 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zometa 4 mg/5 ml koncentrat za otopinu za infuziju zoledronatna kiselina
Zometa concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Koncentrat Zomete ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zometa has been associated with reports of renal dysfunction.
Kao i s drugim bisfosfonatima, zabilježena je povezanost Zomete s poremećajem funkcije bubrega.
Zometa is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Zometa daje se u venu kao infuzija (drip) u trajanju od najmanje 15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
Zometa is not recommended for use in adolescents and children below the age of 18 years.
Ne preporučuje se primjena Zomete u adolescenata i djece mlađe od 18 godina.
Zometa is supplied as a liquid concentrate in a vial.
Zometa se isporučuje kao tekući koncentrat u bočici.
Zometa is supplied as a powder in a vial.
Zometa se isporučuje u obliku praška u bočici.
Zometa is supplied as a solution in a clear, colourless plastic bottle.
Zometa se isporučuje u obliku otopine u prozirnoj, bezbojnoj plastičnoj boci.
Zometa or Aclasta (medicines that also contain zoledronic acid and are used to treat the same disease or cancer diseases of the bone).
Zometu ili Aclastu (lijekove koji također sadrže zoledronatnu kiselinu i koji se koriste za liječenje istih bolesti ili raka kosti).
Zometa or Aclasta (medicines that also contain zoledronic acid and are used to treat the same disease or osteoporosis and other non-cancer diseases of the bone).
Zometu ili Aclastu (lijekove koji također sadrže zoledronatnu kiselinu i koriste se za liječenje osteoporoze i drugih bolesti kostiju koje nisu uzrokovane rakom).
Zometa recommended dose*
Preporučena doza Zomete
Zometa reconstituted solution must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Rekonstituirana otopina Zomete ne smije se miješati s kalcijem ili drugim otopinama za infuziju koje sadrže dvovalentne katione, kao što je otopina Ringerovog laktata, i treba se primijeniti kao jednokratna intravenska otopina kroz posebnu infuzijsku liniju.
Zometa should not be used in pregnant or breast- feeding women.
Lijek se ne smije davati trudnicama niti dojiljama.
Zometa treatment should be resumed at the same dose as that given prior to treatment interruption.
Liječenje Zometom smije se nastaviti istom dozom koja se davala prije prekida liječenja.
Zone diameter (mm)
Zona dijametra (mm)
Zonegran 100 mg hard capsules contain a yellow colour called sunset yellow FCF (E110) and a red colour called allura red AC (E129), which may cause allergic reactions.
Zonegran 100 mg tvrde kapsule sadrže žutu boju pod nazivom sunset yellow FCF (E110) i crvenu boju pod nazivom allura red AC (E129), koje mogu prouzročiti alergijske reakcije.
Zonegran 100 mg hard capsules have a white opaque body and a red opaque cap and are printed with a logo and “ZONEGRAN 100” in black.
Zonegran 100 mg tvrde kapsule imaju bijelo neprozirno tijelo i crvenu neprozirnu kapicu s otisnutim logom i oznakom “ZONEGRAN 100” u crnoj boji.
Zonegran 100 mg orodispersible tablets
Zonegran 100 mg raspadljive tablete za usta
Zonegran 100 mg orodispersible tablets are white to off-white, circular tablets, debossed with the tablet strength (“100”).
Zonegran 100 mg raspadljive tablete za usta bijele su do bjelkaste boje, okrugle, s utisnutom oznakom za jačinu tablete (“100”).
Zonegran 100 mg orodispersible tablets contain 100 mg zonisamide.
Zonegran 100 mg raspadljive tablete za usta sadrže 100 mg zonisamida.
Zonegran 100 mg orodispersible tablets zonisamide
Zonegran 100 mg raspadljive tablete za usta zonisamid
Zonegran 25 mg hard capsules have a white opaque body and a white opaque cap and are printed with a logo and “ZONEGRAN 25” in black.
Zonegran 25 mg tvrde kapsule imaju bijelo neprozirno tijelo i bijelu neprozirnu kapicu s otisnutim logom i oznakom “ZONEGRAN 25” u crnoj boji.
Zonegran 25 mg orodispersible tablets
Zonegran 25 mg raspadljive tablete za usta
Zonegran 25 mg orodispersible tablets are white to off-white, circular tablets, debossed with the tablet strength (“25”).
Zonegran 25 mg raspadljive tablete za usta bijele su do bjelkaste boje, okrugle, s utisnutom oznakom za jačinu tablete (“25”).
Zonegran 25 mg orodispersible tablets contain 25 mg of zonisamide.
Zonegran 25 mg raspadljive tablete za usta sadrže 25 mg zonisamida.
Zonegran 25 mg orodispersible tablets zonisamide
Zonegran 25 mg raspadljive tablete za usta zonisamid
Zonegran 25 mg, 50 mg, 100 mg and 300 mg orodispersible tablets zonisamide
Zonegran 25 mg, 50 mg, 100 mg i 300 mg raspadljive tablete za usta zonisamid
Zonegran 300 mg orodispersible tablets
Zonegran 300 mg raspadljive tablete za usta
Zonegran 300 mg orodispersible tablets are white to off-white, circular tablets, debossed with the tablet strength (“300”).
Zonegran 300 mg raspadljive tablete za usta bijele su do bjelkaste boje, okrugle, s utisnutom oznakom za jačinu tablete (“300”).
Zonegran 300 mg orodispersible tablets contain 300 mg zonisamide.
Zonegran 300 mg raspadljive tablete za usta sadrže 300 mg zonisamida.
Zonegran 300 mg orodispersible tablets zonisamide
Zonegran 300 mg raspadljive tablete za usta zonisamid
Zonegran 50 mg hard capsules have a white opaque body and a grey opaque cap and are printed with a logo and “ZONEGRAN 50” in black.
Zonegran 50 mg tvrde kapsule imaju bijelo neprozirno tijelo i sivu neprozirnu kapicu s otisnutim logom i oznakom “ZONEGRAN 50” u crnoj boji.
Zonegran 50 mg orodispersible tablets
Zonegran 50 mg raspadljive tablete za usta
Zonegran 50 mg orodispersible tablets are white to off-white, circular tablets, debossed with the tablet strength (“50”).
Zonegran 50 mg raspadljive tablete za usta bijele su do bjelkaste boje, okrugle, s utisnutom oznakom za jačinu tablete (“50”).
Zonegran 50 mg orodispersible tablets contain 50 mg of zonisamide.
Zonegran 50 mg raspadljive tablete za usta sadrže 50 mg zonisamida.
Zonegran 50 mg orodispersible tablets zonisamide
Zonegran 50 mg raspadljive tablete za usta zonisamid
Zonegran also acts on the neurotransmitter gamma-aminobutyric acid (GABA, a chemical that allows nerve cells to communicate with each other).
Zonegran također djeluje na neurotransmiter gama amino maslačnu kiselinu (GABA, kemikalija koja omogućava da živčane stanice komuniciraju jedna s drugom).
Zonegran can be taken once or twice daily, as instructed by your doctor.
Zonegran se može uzimati jedanput ili dvaput na dan, prema uputama liječnika.
Zonegran can be taken with or without food.
Zonegran se može uzimati s hranom ili bez nje.
Zonegran capsules must be swallowed whole with water.
Kapsule Zonegrana je potrebno progutati cijele s vodom.
Zonegran could possibly increase your blood levels of medicines like digoxin and quinidine, and so a reduction in their dose may be required.
Zonegran bi mogao povisiti razinu lijekova kao što su digoksin i kinidin u Vašoj krvi, stoga može biti potrebno smanjiti dozu tih lijekova.
Zonegran is meant to be taken as a long-term medicine.
Zonegran je namijenjen kao lijek koji se uzima na dulje vrijeme.
Zonegran must not be used during pregnancy unless clearly necessary, in the opinion of the physician, and only if the potential benefit is considered to justify the risk to the foetus.
Zonegran se ne smije uzimati u trudnoći osim ako je to po mišljenju liječnika nužno potrebno te samo onda kad se smatra da moguća dobrobit opravdava rizik za fetus.
Zonegran orodispersible tablets are bioequivalent to zonisamide hard capsules, with a similar rate and extent of absorption.
Zonegran raspadljive tablete za usta bioekvivalentne su tvrdim kapsulama zonisamida, slične brzine i opsega apsorpcije.
Zonegran orodispersible tablets are for oral use.
Zonegran raspadljive tablete za usta primjenjuju se peroralno.
Zonegran orodispersible tablets are moisture-sensitive, so handle them with dry hands.
Zonegran raspadljive tablete za usta osjetljive su na vlagu pa ih treba dodirivati suhim rukama.
Zonegran orodispersible tablets are packaged in blister packs supplied in boxes containing:
Zonegran raspadljive tablete za usta pakirane su u blisterima koji se nalaze u kutijama koje sadrže:
Zonegran orodispersible tablets are white to off-white, circular tablets, debossed with the tablet strength (“25”, “50”, “100” or “300”).
Zonegran raspadljive tablete za usta bijele su do bjelkaste boje, okrugle s utisnutom jačinom tablete (“25”, “50”, “100” ili “300”).
Zonegran orodispersible tablets contain a sweetener called aspartame (E951), which is a source of phenylalanine and may be harmful for people with phenylketonuria
Zonegran raspadljive tablete za usta sadrže sladilo nazvano aspartam (E951), koje je izvor fenilalanina i može naškoditi osobama koje boluju od fenilketonurije.
Zonegran orodispersible tablets contain a sweetener called aspartame (E951), which is a source of phenylalanine and may be harmful for people with phenylketonuria.
Zonegran raspadljive tablete za usta sadrže sladilo nazvano aspartam (E951), koje je izvor fenilalanina i može naškoditi osobama koje boluju od fenilketonurije.
Zonegran orodispersible tablets may be used as an alternative to Zonegran hard capsules.
Zonegran raspadljive tablete za usta mogu se primjenjivati kao alternativa Zonegran tvrdim kapsulama.
Zonegran should be used carefully in adults when taken with medicines that can cause kidney stones, like topiramate or acetazolamide.
Zonegran u odraslih treba primjenjivati s oprezom kad se uzima s lijekovima koji mogu prouzročiti nastanak bubrežnih kamenaca, poput topiramata ili acetazolamida.
Zonegran was more effective than placebo at reducing the frequency of seizures when used as an ‘add- on’ to existing treatment.
Zonegran je bio djelotvorniji od placeba u redukciji učestalosti napadaja kad se koristi kao „dodatak” postojećem liječenju.
Zonegran with food and drink
Zonegran s hranom i pićem
Zonisamide
kompleksni parcijalni
Zonisamide 100 mg hard capsules:
Zonisamid 100 mg tvrde kapsule:
Zonisamide 25 mg hard capsules:
Zonisamid 25 mg tvrde kapsule:
Zonisamide 50 mg hard capsules:
Zonisamid 50 mg tvrde kapsule:
Zonisamide is 40 – 50 % bound to human plasma proteins, with in vitro studies showing that this is unaffected by the presence of various antiepileptic medicinal products (i.e., phenytoin, phenobarbitone, carbamazepine, and sodium valproate).
Zonisamid je 40 - 50% vezan na humane proteine u plazmi, s tim da ispitivanja in vitro pokazuju da na to ne utječe prisutnost različitih antiepileptičkih lijekova (tj. fenitoina, fenobarbitona, karbamazepina i natrijeva valproata).
Zonisamide lowers the 28-day average seizure frequency and the decrease is proportional (log-linear) to zonisamide average concentration.
Zonisamid snižava 28-dnevnu prosječnu učestalost napadaja a smanjenje je proporcionalno (log-linearno) prosječnoj koncentraciji zonisamida.
Zonisamide must not be used during pregnancy unless clearly necessary, in the opinion of the physician, and only if the potential benefit is considered to justify the risk to the foetus.
Zonisamid se ne smije uzimati u trudnoći osim ako je to po mišljenju liječnika nužno potrebno te samo onda kad se smatra da moguća dobrobit opravdava rizik za fetus.
Zonisamide Mylan 100 mg are available in blister packs of 28, 56, 98 and 196 capsules and perforated unit dose blister packs of 56 x 1 capsules.
Zonisamid Mylan 100 mg dostupan je u blister pakiranjima s 28, 56, 98 i 196 kapsula i perforiranim blister pakiranjima djeljivim na jedinične doze s 56 x 1 kapsulom.
Zonisamide Mylan 100 mg hard capsules
Zonisamid Mylan 100 mg tvrde kapsule
Zonisamide Mylan 100 mg hard capsules have a white body and white cap, marked “Z 100” in black and contain a white/almost white powder.
Zonisamid Mylan 100 mg tvrde kapsule imaju bijelo tijelo i bijelu kapicu s crnom oznakom “Z 100” i sadrže bijeli/gotovo bijeli prašak.
Zonisamide Mylan 100 mg hard capsules zonisamide
Zonisamid Mylan 100 mg tvrde kapsule zonisamid
Zonisamide Mylan 25 mg and 100 mg hard capsules
Zonisamid Mylan 25 mg i 100 mg tvrde kapsule
Zonisamide Mylan 25 mg and 50 mg are available in blister packs of 14, 28, 56 capsules and perforated unit dose blister packs of 14 x 1 capsules.
Zonisamid Mylan 25 mg i 50 mg dostupni su u blister pakiranjima s 14, 28, 56 kapsula i perforiranim blister pakiranjima djeljivim na jedinične doze s 14 x 1 kapsulom.
Zonisamide Mylan 25 mg and 50 mg hard capsules
Zonisamid Mylan 25 mg i 50 mg tvrde kapsule
Zonisamide Mylan 25 mg hard capsules
Zonisamid Mylan 25 mg tvrde kapsule
Zonisamide Mylan 25 mg hard capsules have a white body and a white cap, marked “Z 25”in black and contain a white/almost white powder.
Zonisamid Mylan 25 mg tvrde kapsule imaju bijelo tijelo i bijelu kapicu s crnom oznakom “Z 25” i sadrže bijeli/gotovo bijeli prašak.
Zonisamide Mylan 25 mg hard capsules zonisamide
Zonisamid Mylan 25 mg tvrde kapsule zonisamid
Zonisamide Mylan 25 mg hard capsules Zonisamide Mylan 50 mg hard capsules Zonisamide Mylan 100 mg hard capsules
Zonisamid Mylan 25 mg tvrde kapsule Zonisamid Mylan 50 mg tvrde kapsule Zonisamid Mylan 100 mg tvrde kapsule
Zonisamide Mylan 25 mg hard capsules Zonisamide Mylan 50 mg hard capsules Zonisamide Mylan 100 mg hard capsules zonisamide
Zonisamid Mylan 25 mg tvrde kapsule Zonisamid Mylan 50 mg tvrde kapsule Zonisamid Mylan 100 mg tvrde kapsule zonisamid
Zonisamide Mylan 50 mg hard capsules
Zonisamid Mylan 50 mg tvrde kapsule
Zonisamide Mylan 50 mg hard capsules have a white body and white cap, marked “Z 50” in red and contain a white/almost white powder.
Zonisamid Mylan 50 mg tvrde kapsule imaju bijelo tijelo i bijelu kapicu s crvenom oznakom “Z 50” i sadrže bijeli/gotovo bijeli prašak.
Zonisamide Mylan 50 mg hard capsules zonisamide
Zonisamid Mylan 50 mg tvrde kapsule zonisamid
Zonisamide Mylan also acts on the neurotransmitter gamma‑aminobutyric acid (GABA, a chemical that allows nerve cells to communicate with each other).
Zonisamid Mylan također djeluje na neurotransmiter gama — aminomaslačnu kiselinu (GABA, kemikalija kojom se omogućuje da živčane stanice komuniciraju jedna s drugom).
Zonisamide Mylan belongs to a group of medicines (sulfonamides) that can cause severe allergic reactions, severe skin rashes, and blood disorders, which very rarely can be fatal.
Zonisamid Mylan pripada skupini lijekova (sulfonamida) koji mogu uzrokovati teške alergijske reakcije, teške osipe na koži i poremećaje krvi, vrlo rijetko sa smrtnim ishodom.
Zonisamide Mylan can be taken once or twice daily, as instructed by your doctor.
Zonisamid Mylan se može uzimati jedanput ili dvaput na dan, prema uputama liječnika.
Zonisamide Mylan can be taken with or without food.
Zonisamid Mylan se može uzimati s hranom ili bez nje.
Zonisamide Mylan can cause your child to sweat less and overheat and if your child is not treated this can lead to brain damage and death.
Zonisamid Mylan može u Vašeg djeteta prouzročiti smanjeno znojenje i pregrijavanje, pa ako se dijete ne liječi to može dovesti do oštećenja mozga i smrti.
Zonisamide Mylan capsules must be swallowed whole with water.
Kapsule lijeka Zonisamid Mylan je potrebno progutati cijele s vodom.
Zonisamide Mylan contains the active substance zonisamide, and is used as an antiepileptic medicine.
Zonisamid Mylan sadrži djelatnu tvar zonisamid i koristi se kao lijek protiv epilepsije.
Zonisamide Mylan could possibly increase your blood levels of medicines like digoxin and quinidine, and so a reduction in their dose may be required.
Zonisamid Mylan bi mogao povisiti razinu lijekova kao što su digoksin i kinidin u Vašoj krvi, stoga može biti potrebno smanjiti dozu tih lijekova.
Zonisamide Mylan hard capsules are for oral use.
Zonisamid Mylan tvrde kapsule primjenjuju se peroralno.
Zonisamide Mylan is a ‘generic medicine’.
Zonisamid HCS je „generički lijek”.
Zonisamide Mylan is indicated as:
Zonisamid Mylan je indiciran kao:
Zonisamide Mylan is meant to be taken as a long-term medicine.
Zonisamid Mylan je namijenjen kao lijek koji se uzima na dulje vrijeme.